Tecotabart vedotin: Sino Biopharm has bet on a global first — where is the real exam?

At the molecular level, LM-302 is a Claudin18.2 ADC of standard structure — a humanized anti-CLDN18.2 monoclonal antibody + a protease-cleavable linker + MMAE, DAR about 4. The target has been fully validated by Astellas's zolbetuximab in two Phase 3 trials, SPOTLIGHT/GLOW (median OS 14.4 months, HR ≈ 0.75); approved by FDA in 2024 and by the NMPA in January 2025. Target validation risk has already been underwritten by others.

Clinical data: a 153-patient Phase 1/2 (European Journal of Cancer, 2025-09): recommended dose 1.8 mg/kg Q2W; in CLDN18.2+ gastric/gastroesophageal junction cancer patients who had failed at least 2 prior lines of systemic therapy, ORR 32.7% and median PFS 4.9 months; peripheral neuropathy and neutropenia were the main grade ≥3 adverse events, with none of zolbetuximab's typical GI-specific infusion reactions observed. The combination data presented at ASCO 2025 were brighter: LM-302 + toripalimab in first-line CLDN18.2+ gastric cancer gave ORR 65.9%, rising to 71.9% in the subgroup with CLDN18.2 expression ≥25%. This is the differentiation story most worth telling for an ADC relative to a monoclonal antibody — additive efficacy + flexibility in expression stratification.

At the company level, LM-302 landing in Sino Biopharm's hands was both accidental and inevitable. In 2024 Sino Biopharm had revenue of RMB 28.87 billion, innovative product revenue of RMB 12.06 billion (41.8% of the total) and R&D spending at 17.6% of revenue, with 17 innovative products marketed and a plan to exceed 30 by 2027; the company explicitly lists "going global + ADCs + bispecifics + KRAS" as its four main lines. LaNova's ADC platform, plus the three assets LM-299 (a PD-1/VEGF bispecific, licensed out to MSD for US$3.3 billion in November 2024), LM-305 (a GPRC5D ADC, licensed to AZ) and LM-302, are essentially the core ROI anchors for the US$951 million Sino Biopharm paid for LaNova.

LM-302's position in the global ranking of CLDN18.2 ADCs is easy to state — right now it is first. Trailing it by 12–18 months are AZ/Keymed's CMG901/AZD0901 (CLARITY-Gastric 01 Phase 3 enrolling), Innovent's IBI343 (pancreatic cancer Phase 3 started; gastric cancer still at an earlier stage) and Evopoint Biosciences' XNW27011 licensed to Astellas (Phase 2; license deal of 2025-05 with US$130 million upfront + up to US$1.34 billion, using a Topo-I payload). Further back are CSPC/Elevation's EO-3021, Antengene's ATG-022, RemeGen's RC118 and others.

But "global first" is a concept of a time window, not a claim about absolute efficacy. LM-302's single-agent ORR of 32.7% and CMG901's Phase 1 single-agent ORR of 33% are almost identical; in combination, LM-302 + toripalimab in first line gives a high ORR of 66–72%, the strongest combination signal read out so far among CLDN18.2 ADCs, but not yet in Phase 3.

This means LM-302's strategic proposition is: trading a time gap for BD valuation and the dividend of first approval in China — converting the scarcity of "the first to read out Phase 3 OS" into a China NDA in 2027–2028 and into bargaining chips with MNC partners. The hard constraint is that Phase 3 OS must read out, and the HR must be good enough (below 0.75 is the ideal range, 0.75–0.85 is negotiable, above 0.85 the timing advantage is swallowed by insufficient efficacy).

The China registration path is almost textbook-clear: an independent Chinese Phase 3, TPC comparator, OS primary endpoint, CLDN18.2 IHC enrichment, conditional approval pathway. LaNova has been in continuous communication with CDE since 2022, and two Breakthrough Therapy Designations (≥3L monotherapy + 1L + toripalimab) have landed in succession. After the acquisition Sino Biopharm took over the CDE relationship, and Chia Tai Tianqing's registration experience (anlotinib's nine indications, accelerated approval of the KRAS G12C inhibitor garsorasib) strengthens project capability.

Projecting the specific timeline: the Phase 3 OS interim reads out roughly from late 2026 to H1 2027; if the interim data are good enough Sino Biopharm can go for a conditional NDA, with submission locked for H2 2027 and approval after a 9–12-month review — launch should come in 2028. The key point about this timing is that it lands exactly in the 2028 NRDL negotiation window (the National Healthcare Security Administration negotiates from July to November each year), avoiding a gap period of "launched but unable to get NRDL coverage".

This is LM-302's most underrated and most stable path to value realization in China, and the core narrative that distinguishes Sino Biopharm as a large pharma from an ordinary domestic biotech. Three layers:

The first layer is direct departmental coverage by the commercial team. Chia Tai Tianqing's oncology division covers 3,000+ tertiary and secondary hospitals nationwide, and access pathways in gastric cancer departments have already been worked out by anlotinib — anlotinib now has 9 approved indications and 4 under CDE review, with GI-related indications contributing significant accumulated departmental relationships. When LM-302 launches, the key gastric cancer PIs (Shen Lin, Xu Ruihua, Qin Shukui, etc.) are precisely the Phase 3 PIs, so the commercial team can plug in on day one rather than build an academic network from scratch.

The second layer is synergy with products in the portfolio. Two lines here: first, pairing LM-302 with anlotinib in later-line gastric cancer (anlotinib is anti-angiogenic, LM-302 targets CLDN18.2, with complementary mechanisms); second, combination with toripalimab (developed by Junshi, in which Sino Biopharm has collaboration rights) — the real main battlefield proposition in 1L gastric cancer. Zolbetuximab + chemo has already pushed 1L OS to 14.4 months, and LM-302 + toripalimab first-line data at ASCO 2025 showed ORR 65.9%; if the 1L Phase 3 can beat zolbetuximab + chemo, first-line gastric cancer in China will be rewritten and the single-product peak sales ceiling fully opened.

The third layer is no self-cannibalization in the portfolio. Sino Biopharm's other ADC flagship is Chia Tai Tianqing's TQB2102 (a HER2 biparatopic ADC with three Phase 3 trials in breast cancer). HER2 positivity and CLDN18.2 positivity overlap by less than 10% in gastric cancer, so the two are complementary rather than competing in gastric cancer — TQB2102 covers HER2+ patients and LM-302 covers CLDN18.2+/HER2- patients, giving Sino Biopharm, in effect, a "two ADCs take all" position in gastric cancer. A standalone biotech cannot do this.

Putting these three layers together, the commercialization infrastructure Sino Biopharm has prepared for LM-302 far exceeds the resources LaNova could have deployed operating independently — which is also why LaNova's founding team ultimately accepted the US$951 million acquisition price: LM-302's real NPV in China is far higher than the risk-adjusted NPV under independent biotech operation.

ADC CMC is not a difficulty unique to LM-302 but an industry-wide issue: DAR must be controlled within ±0.5, free payload must be below ICH Q6B limits, comparability studies between commercial and clinical batches must withstand NMPA and FDA scrutiny, ADC CDMO capacity is globally scarce, and order lead times are generally ≥18 months. Sino Biopharm's CMC resources in China are good — LaNova's existing ADC process facilities + Chia Tai Tianqing's own ADC platform (TQB2102 already in three Phase 3 trials) + ADC CDMOs such as WuXi Biologics / Shanghai STA / TOT Biopharm as backup, giving sufficient redundancy for commercial supply.

The real break point is overseas. LaNova's existing ADC facility has not been through an FDA pre-approval inspection, and at group level Sino Biopharm also lacks the piece of an "FDA-inspected ADC plant". As of 2026, cases of Chinese ADCs successfully passing FDA inspection are still rare — an objective but often underestimated bottleneck on the road abroad.

There are only two realistic solutions: first, Sino Biopharm invests in 2026–2027 to upgrade its existing ADC facility to FDA standards and proactively runs a mock inspection; second, hand this to a BD partner — a partner with its own FDA-inspected facility (BMS, MSD and Pfizer all have them) can take over ex-China supply. Which road is cheaper, which is faster and which preserves more valuation will become core terms at the BD negotiating table. No license-in constraints on payload IP (MMAE's chemical structure is public; LaNova's process is in-house) is a hidden advantage of LM-302 — there will be no royalty stacking in a license, a difference worth several percentage points in BD valuation.

Looking back: in May 2022, LaNova licensed LM-302's global rights ex-(Greater China + Korea) to Turning Point Therapeutics for US$25 million upfront and a total of more than US$1 billion. Three months later BMS acquired Turning Point for US$4.1 billion and took over the LM-302 agreement. In the second half of 2024, BMS quietly returned LM-302's overseas rights without a standalone press release — with an upfront of only US$25 million and low book value, the internal decision was most likely that its priority had been crowded out by new-generation Topo-I payload ADC assets.

So today LM-302's overseas rights are fully back within the Sino Biopharm group, but Sino Biopharm has no ready-made overseas development and commercial team. This means that on the overseas path, "self-commercialization" is almost infeasible; "re-licensing out" is the most realistic choice; and "regional licensing" is the fallback option. As a comparable, Sino Biopharm already licensed LaNova's LM-299 (a PD-1/VEGF bispecific) to MSD in November 2024 for US$3.3 billion — US$588 million upfront, up to US$2.7 billion in milestones, with MSD triggering an additional US$300 million after technology transfer was completed in 2025. That deal is both a model of maximizing BD value and a source of practical experience and an MSD relationship for LM-302.

Partner shortlist (inferred from public information): BMS (though it exited, it may come back after internal ADC strategy adjustments), MSD (existing LM-299 relationship with Sino Biopharm), Pfizer (ADC standard-bearer after the Seagen acquisition), Daiichi (already partnered with AZ on DS-8201; a CLDN18.2 ADC is a potential gap-filler), Roche, Takeda. Astellas already holds XNW27011 + zolbetuximab and is unlikely to take LM-302 as well. AZ already has CMG901 (via Keymed).

Sino Biopharm paid US$951 million to acquire LaNova (about US$500 million net after deducting LaNova's cash at closing), and the return on this money has three anchors: the first is LM-299, already licensed to MSD with up to US$3.3 billion locked in as triggerable; the second is LM-302's China sales + overseas license-out; the third is the remaining pipeline such as LM-108 and LM-305 plus the reuse value of LaNova's ADC/bispecific platform. Among the three anchors, LM-302 is the one with "the fastest commercial realization and the greatest valuation elasticity" — both because it has already completed Phase 3 enrollment and because its overseas rights are available again.

At the portfolio level, Sino Biopharm explicitly lists "going global + ADCs + bispecifics + KRAS" as its four main lines. LM-302 carries both the "going global" and "ADC" lines, scoring full marks on strategic consistency. There is no overlapping CLDN18.2 asset in the portfolio, and it is complementary with the TQB2102 HER2 ADC in the gastric cancer patient pool, so resource conflict is low. The R&D budget (group R&D spending at 17.6% of revenue in 2024, about RMB 5 billion in absolute terms) can fully cover spending on LM-302's Phase 3 + 1L combination + CMC scale-up (estimated at RMB 300–500 million a year).

The real resource constraints are in two places: first, commercial team bandwidth — Chia Tai Tianqing's oncology division is simultaneously carrying anlotinib, garsorasib, TQB2102 and LM-302, and if 1–2 more oncology NDAs launch in the next two years, bandwidth will reach its limit; second, the ability to execute overseas BD negotiations — Sino Biopharm's BD team has completed several deals in recent years, including LM-299/MSD, LM-305/AZ and the exclusive license of rovadicitinib to Sanofi, but its ability to sustain dialogue with top-tier MNCs on large ADC deals is still being built, with room to grow compared with more internationalized rivals such as BeiGene and HUTCHMED.

Events that could overturn the current judgment:

The story of tecotabart vedotin is only half told as of today. The first half — from LaNova's in-house discovery to BMS's exit and back to Sino Biopharm — has already happened; the second half — Phase 3 OS data, the China NDA, overseas BD, and market confrontations with zolbetuximab and CMG901 — will be decided within the two years of 2026–2028.

For Sino Biopharm, LM-302 is both the core asset for validating "the ROI of the LaNova acquisition" and a live case study for landing the twin strategic lines of "going global + ADCs" on a concrete asset. In the Chinese market it will deliver a visible sales curve through Chia Tai Tianqing's gastric cancer platform, and overseas BD will test whether the hybrid model of "BD-driven integration + platform leverage" can truly support a domestic large pharma's internationalization narrative.

What is most worth watching is not the Phase 3 OS number itself, but how Sino Biopharm, over 2026–2027, uses governance structure, portfolio resources and BD timing to convert the scarcity of "the first globally to complete Phase 3 enrollment" into tradable global value. LM-302 is not just a CLDN18.2 ADC; it is a real exam question on "how a large Chinese pharma does globalization" — and Sino Biopharm is writing its answer.